Galimedix Therapeutics presents sturdy pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026

Priavoid Presents Preclinical Proof-of-Idea for PRI-101 Demonstrating α-synuclein Mixture Disassembly at AD/PD™ 2026